What is the Cost of Rinvoq?
The price of Rinvoq (upadacitinib) can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. As of late 2023, the estimated retail price for a 30-day supply of Rinvoq 15 mg extended-release tablets can range from $6,500 to over $7,000 [1]. Prices can fluctuate, and obtaining an exact cost typically requires consulting with a pharmacy or insurance provider.
How Does Insurance Affect Rinvoq Pricing?
Insurance plans often provide coverage for Rinvoq, but the out-of-pocket cost to patients depends on their specific policy. This includes the deductible, copay, and coinsurance. Many insurance providers may require prior authorization before covering Rinvoq, and some may place it on a tiered formulary, impacting the patient's cost [2]. Manufacturer savings programs may also be available for eligible commercially insured patients to help reduce out-of-pocket expenses [3].
What are Rinvoq's Approved Uses?
Rinvoq is approved to treat several conditions. These include moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF antagonists [4]. It is also indicated for active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe atopic dermatitis in adults and a subset of children [4]. Additionally, Rinvoq is used for moderately to severely active ulcerative colitis in adults who have had an inadequate response, loss of response, or intolerance to a biologic or to conventional therapy [4].
When Does Rinvoq's Patent Expiry Occur?
Patent expiry dates for pharmaceuticals like Rinvoq are crucial for the potential introduction of generic alternatives, which could lead to lower prices. DrugPatentWatch.com tracks these patents and their timelines. While specific patent expiry dates can be complex due to multiple patents covering different aspects of a drug (e.g., formulation, manufacturing processes, methods of use), the primary patents for upadacitinib (the active ingredient in Rinvoq) are expected to expire in the coming years [5]. For detailed and up-to-date patent information, DrugPatentWatch.com offers comprehensive data [5].
Who are Rinvoq's Competitors?
Rinvoq competes in the Janus kinase (JAK) inhibitor class and broader immunomodulatory drug markets. Key competitors include other JAK inhibitors such as Xeljanz (tofacitinib) and Cibinqo (abrocitinib). In the treatment of inflammatory conditions, it also faces competition from biologic therapies like adalimumab (Humira) and ustekinumab (Stelara) [6].
What are the Side Effects of Rinvoq?
Common side effects of Rinvoq can include upper respiratory tract infections, acne, cough, fever, and changes in cholesterol levels [4]. More serious risks include infections, blood clots, heart attack, stroke, cancer, and a boxed warning regarding the increased risk of death in certain patients when used with prescription doses of 5 mg or higher of tofacitinib (another JAK inhibitor) compared to TNF inhibitors [4]. Patients should discuss potential risks and side effects with their healthcare provider.
Can Biosimilars or Generics of Rinvoq Enter the Market?
The introduction of biosimilars (for biologic drugs) or generics (for small molecule drugs like Rinvoq) is contingent upon patent expiry and regulatory approval. For Rinvoq, the development and approval of generic versions will be possible after the relevant patents expire and the U.S. Food and Drug Administration (FDA) deems a generic equivalent to be safe and effective. This process can take several years following patent expiration [5].
Sources:
[1] https://www.goodrx.com/rinvoq
[2] https://www.rinvoq.com/insurance-and-financial-assistance
[3] https://www.rinvoq.com/insurance-and-financial-assistance/savings-programs
[4] https://www.rinvoq.com/about-rinvoq
[5] https://drugpatentwatch.com/ (Refer to specific drug search on the website for upadacitinib)
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442397/